SlideShare a Scribd company logo
Insulin Therapy
Initiation and Adjustment
Dr Shahjada Selim
Endocrinologist
Registrar, Department of Medicine, ShSMCH
1
Issues in the Management of
Type 2 Diabetes
• Type 2 DM is a chronic condition with
progressive loss of beta-cell function over time
• Increasing prevalence with obesity
• Hyperglycemia affects morbidity, mortality
• Tight glycemic control with insulin may reduce
costly complications
2
3
• 30% to 40% of patients ultimately require
insulin.
• Newer semisynthetic or analog insulins
and delivery systems may improve
compliance and achieve better glycemic
control with less hypoglycemia.
…………………Conted
Defined glycemic targets in T2DM
PG=plasma glucose.
1. American Diabetes Association. Diabetes Care 2005;28(suppl 1):S14—36.
2. American Association of Clinical Endocrinologists. Endocr Pract 2002;8(suppl 1):43—84.
3. International Diabetes Federation. Diabet Med 1999;16:716—30.
*1−2 hours postprandial; **2 hours postprandial.
Glucose control Healthy ADA1
AACE2
IDF3
HbA1c (%) <6 <7 ≤6.5 ≤6.5
Mean FPG
mmol/l (mg/dl)
<5.6
(<100)
5−7.2
(90−130)
<6
(<110)
<6
(<110)
Mean
postprandial PG
mmol/l (mg/dl)
<7.8
(<140)
<10*
(<180)
<7.8**
(<140)
<7.5**
(<135)
4
The Goal of Insulin Therapy:
Attempt to Mimic Normal Pancreatic Function
Schade, Skyler, Santiago, Rizza, “Intensive Insulin Therapy,” 1993, p. 131.
0
6 0
3 0
1 0 0
6 0
1 4 0
1 5
1 9 3 0
H O U R S
2 3 3 0 0 3 3 0 0 7 3 01 5 3 01 1 3 03 3 0
8 0
4 0
1 2 0
7 5
1 6 0
P L A S M A
G L U C O S E
m g / d l
B L S H S
P L A S M A F R E E
IN S U L IN
u / m l
Purpose of Insulin Therapy
• Prevent and treat fasting and postprandial
hyperglycemia
• Permit appropriate utilization of glucose and
other nutrients by peripheral tissues
• Suppress hepatic glucose production
• Prevent acute complications of uncontrolled
diabetes
• Prevent long term complications of chronic
diabetes 6
All type 1 diabetics should be on a
Bolus-bolus insulin regimen to
control glucose while minimizing
hypoglycemia.
6-19
However over time, most type 2
diabetics will also need both basal
and mealtime insulin to control
glucose.
6-19
Initiating Insulin Therapy
6-36
Patient Concerns About Insulin
• Fear of injections
• Perceived significance of need for insulin
• Worries that insulin could worsen diabetes
• Concerns about hypoglycemia
• Complexity of regimens
10
When to Start Insulin?
• Watch for the following signs
– Increasing BG levels
– Elevated A1C
– Unexplained weight loss
– Traces of ketonuria
– Poor energy level 11
When OHAs are not enough to achieve
target glycemic status --
…..When Oral Medications Are Not Enough
– Sleep disturbances
– Polydipsia
• Next steps
– Make a decision to start insulin
– Offer patient encouragement, not blame
12
…..Initiating Insulin Therapy in Type 2 Diabetes
• Let blood glucose levels guide choice
of insulins
– Select type(s) of insulin and timing
of injection(s) based on pattern of
patient’s sugar (fasting, lunch,
dinner, bedtime)
13
….Initiating Insulin Therapy in Type 2 Diabetes
• Choose from currently available insulin
preparations
– Rapid-acting (mealtime): lispro, aspart,
glulisine
– Short-acting (mealtime): regular insulin
– Intermediate-acting (background): NPH,
lente
– Long-acting (background): degledec,
ultralente, glargine
– Insulin mixtures (premixed)
….Initiating Insulin Therapy in Type 2 Diabetes
• Provide long-acting or intermediate-
acting as basal and rapid-acting as bolus
• Titrate every week
Goal: to approximate endogenous insulin secretion…
The ADA TreatmentThe ADA Treatment
Algorithm for the Initiation andAlgorithm for the Initiation and
Adjustment of InsulinAdjustment of Insulin
16
Step One: Initiating InsulinStep One: Initiating Insulin
• Start with either…
– Bedtime long-acting/intermediate acting
insulin
Insulin regimens should be designed taking
lifestyle and meal schedules into account
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.17
Step One: Initiating InsulinStep One: Initiating Insulin, cont’d, cont’d
• Check fasting glucose and increase dose
until in target range
– Target range: 3.89-7.22 mmol/l (70-130 mg/dl)
– Typical dose increase is 2 units every 3 days,
but if fasting glucose >10 mmol/l (>180 mg/dl),
can increase by large increments (e.g., 4 units
every 3 days).
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.18
• If hypoglycemia occurs or if fasting glucose
>3.89 mmol/l (70 mg/dl)…
– Reduce bedtime dose by ≥4 units or 10%
if dose >60 units
Step One: Initiating InsulinStep One: Initiating Insulin, cont’d, cont’d
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.19
• If HbA1c is <7%...
– Continue regimen and check HbA1c every
3 months
• If HbA1c is ≥7%...
– Move to Step Two…
After 2-3 Months…After 2-3 Months…
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.20
Initiating and Adjusting InsulinInitiating and Adjusting Insulin
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime intermediate-acting insulin, or
bedtime or morning long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
If HbA1c ≤7%... If HbA1c ≥7%...
21
Step One…
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
If HbA1c ≤7%... If HbA1c ≥7%...
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
22
Step Two: Intensifying InsulinStep Two: Intensifying Insulin
If fasting blood glucose levels are in target
range but HbA1c ≥7%, check blood glucose
before lunch, dinner, and bed and add a
second injection:
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.23
Step Two: Intensifying InsulinStep Two: Intensifying Insulin
• If pre-lunch blood glucose is out of range,
add rapid-acting insulin at breakfast
• If pre-dinner blood glucose is out of range,
add NPH insulin at breakfast or rapid-
acting insulin at lunch
• If pre-bed blood glucose is out of range,
add rapid-acting insulin at dinner
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.24
Insulin AdjustmentsInsulin Adjustments
• Can usually begin with ~4 units and
adjust by 2 units every 3 days until
blood glucose is in range.
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.25
• If HbA1c is <7%...
– Continue regimen and check HbA1c every
3 months
• If HbA1c is ≥7%...
– Move to Step Three…
After 2-3 Months…After 2-3 Months…
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.26
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
If HbA1c ≤7%... If HbA1c ≥7%...
Step Two…
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
27
Step Three:Step Three:
Further Intensifying InsulinFurther Intensifying Insulin
• Recheck pre-meal blood glucose and
if out of range, may need to add a third
injection:
• If HbA1c is still ≥ 7%
–Check 2-hr postprandial levels
–Adjust preprandial rapid-acting insulin
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.28
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
If HbA1c ≤7%... If HbA1c ≥7%...
Step Three…
29
Premixed InsulinPremixed Insulin
• Not recommended during dose
adjustment .
• Can be used before breakfast and/or
dinner if the proportion of rapid- and
intermediate-acting insulin is similar
to the fixed proportions available
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.30
Basal Insulins in Type 2 DM
• NPH at HS - duration of action short:
- usually need AM injection
- nighttime hypoglycemia a
problem
31
Basal Insulins in Type 2 DM
• Analogs
- Degludec - true once daily injection
- Glargin - likely to succeed as true once
daily injection
- Detemir – Basal insulin
32
Inhaled InsulinInhaled Insulin
• Approved in the U.S. in 2006 for the
treatment of type 2 diabetes and then had
been withdrawn from the market.
• In June, 2014 another inhaled insulin
(Afreeza) got US FDA approval and Aventis
bought the patent of it for commercial
production and marketing.
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.33
Upgrade and Intensification
Selecting alternative insulin or altering
the current treatment regimen (e.g.
Increasing number of daily doses)
Need of Changing Insulin Regimen
• Failure to attain or maintain target
glycemic status (FPG/PPG or HbA1C).
• H/O repeated hypoglycemia
• Lifestyle issues
Changing from Other regimens to
Basal/Bolus Insulin
~50%
Basal*
Total Daily DoseTotal Daily Dose
(~70-75% of prior insulin regimen TDD)(~70-75% of prior insulin regimen TDD)
~50%
Bolus*
Usually divided into 3 premealUsually divided into 3 premeal
dosesdoses*Range: 40 to 60%*Range: 40 to 60%
An Example:
• Mr. M: 58 yrs with history type 2 diabetes for
8 years
– In addition to OHAs, he is on 70/30 premixed
insulin: 30 u AM and 15 u PM
– Current Total Daily Dose = 45 u of 70/30
– However, he has been having difficulty with
wide glycemic excursions.
………….An Example:
• After discussing his options in detail, he
is willing to begin with basal/bolus
regimen:
• New TDD= 45 u x .75 = 33.75 = 34 u
– Basal = 17 u Degludec at bedtime
– Bolus = 17 u total / 3 = 5.6 u = 5 u
aspart/Glulisine immediately before meals.
Another method
• Same patient: Mr. M on 70/30 insulin:
30 u AM and 15 u PM
– Current Total Daily Dose = 45 u of 70/30
• Instead, some clinicians prefer to
instead calculate the new basal/bolus
doses independently of each other
– Current Basal= 0.70 x 45 u TDD = 31.5 u N
– Current Bolus= 0.30 x 45 u TDD = 13.5 u.
………….Another method
• Then, use 70 to 75% of prior NPH,
but divide prior short acting into 3
premeal doses
– New Basal= 0.75 x 31.5 u N = 24 u
Degludec, Glargine, Detemir.
– New Bolus= 13.5 u R / 3 = 4.5 u (round up
or down) Aspart or Glulisine
So which method is best?
• This is where the “Art of Medicine”
comes in:
– If patient has been having difficulty with
hypoglycemia, then start any new insulin
regimen with conservative doses.
– If patient, on the other hand, has been having
hyperglycemia, then one can be more
aggressive.
Remember: every patient is an individual!
A Quick Word on using Sliding
Scale Insulin….
Don’t!
Instead of Sliding Scale....
• Basal insulin is necessary even in the fasting
state
• Sliding scales do not provide physiologic insulin
needs
• Sliding scales often result in “chasing” of
blood sugars
• There can be wide glycemic excursions
Remember: Just because a diabetic’s FBG is <150 does not mean
that they need no insulin!
Think Supplementation or Correction Scale…
The Solution:
• In acutely ill hospitalized diabetics:
use continuous IV insulin
………The Solution:
• If one must use an insulin scale in an outpatient or
stable inpatient setting:
• Insulin scale should only supplement a routine
scheduled regimen of basal and premeal insulin
• May use to correct for hyperglycemia between
scheduled doses of insulin
• It should NEVER be ordered such that the scale is
the only source of insulin for the patient
Drawbacks of intensive
insulin regimens
• Requires frequent monitoring of glucose
• Multiple daily injections of insulin
• Requires intensive patient education/on-
going support
• Newer insulin analogues require less
injections a but are more expensive 47
Key Take-Home MessagesKey Take-Home Messages
• Insulin is the oldest, most studied, and most
effective antihyperglycemic agent, but can
cause weight gain (2-4 kg) and
hypoglycemia.
• Insulin analogues with longer, non-peaking
profiles may decrease the risk of
hypoglycemia compared with NPH insulin.
48
Key Take-Home MessagesKey Take-Home Messages
• Premixed insulin is not recommended
during dose adjustment.
49
Key Take-Home MessagesKey Take-Home Messages
• When initiating insulin, start with bedtime
or morning long-acting insulin.
• After 2-3 months, if FBG levels are in
target range but HbA1c ≥7%, check BG
before lunch, dinner, and bed,
and, depending on the results, add 2nd
injection.
50
Key Take-Home MessagesKey Take-Home Messages
• After 2-3 months, if pre-meal BG out of
range, may need to add a 3rd
injection; if
HbA1c is still ≥7% check 2-hr postprandial
levels and adjust preprandial rapid-acting
insulin.
• Adjust one insulin at a time. Begin with the
insulin that will correct the first problem
blood glucose of the day.
51
Key Take-Home MessagesKey Take-Home Messages
• It is difficult to obtain optimal control
without occasional, mild episodes of
hypoglycemia.
52
53
Thanks to All

More Related Content

What's hot

Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
Dr. Aryan (Anish Dhakal)
 
Insulin therapy dr shahjadaselim
Insulin therapy dr shahjadaselimInsulin therapy dr shahjadaselim
Insulin therapy dr shahjadaselim
Bangabandhu Sheikh Mujib Medical University
 
Basics of insulin therapy
Basics of insulin therapy Basics of insulin therapy
Basics of insulin therapy
Mohsen Eledrisi
 
Insulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetesInsulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetes
Mohsen Eledrisi
 
Management of inpatient hyperglycemia
Management of inpatient hyperglycemiaManagement of inpatient hyperglycemia
Management of inpatient hyperglycemia
Dr. Armaan Singh
 
hypoglycemia
hypoglycemiahypoglycemia
hypoglycemia
Ahmed Dabour
 
DKA
DKADKA
Managing Diabetes With Insulin by Dr Shahjada Selim
Managing DiabetesWith Insulin by Dr Shahjada SelimManaging DiabetesWith Insulin by Dr Shahjada Selim
Managing Diabetes With Insulin by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
HYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCYHYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCY
Abhinav Srivastava
 
Hyperosmolar hyperglycemic state
Hyperosmolar hyperglycemic stateHyperosmolar hyperglycemic state
Hyperosmolar hyperglycemic state
Dr. Mohammed Sadiq Azam M.D.
 
Atrial Fibrillation
Atrial FibrillationAtrial Fibrillation
Atrial Fibrillation
meducationdotnet
 
2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf
Meccar Moniem Elino
 
Insulin in icu 2
Insulin in icu 2Insulin in icu 2
Insulin in icu 2
Dr.Tarek Sabry
 
Hypoglycemia in Adults
Hypoglycemia in AdultsHypoglycemia in Adults
Hypoglycemia in Adults
Dr Shumayla Aslam-Faiz
 
Insulin22
Insulin22Insulin22
Insulin22
Praveen Nagula
 
Diabetes care in hospital
Diabetes care in hospitalDiabetes care in hospital
Diabetes care in hospital
Dr.Jithesh.K,MD(Med) MBA(Hosp.Admin)
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
Anas Bahnassi أنس البهنسي
 
Insulin therapy in IDDM by Dr. Dilip
Insulin therapy in IDDM by Dr. DilipInsulin therapy in IDDM by Dr. Dilip
Insulin therapy in IDDM by Dr. Dilip
DrDilip86
 
Hyperglycaemic emergencies in Diabetes mellitus
Hyperglycaemic emergencies in Diabetes mellitusHyperglycaemic emergencies in Diabetes mellitus
Hyperglycaemic emergencies in Diabetes mellitus
Kapil Dhingra
 
Insulin therapy for type 2 diabetes patients dr shahjadaselim1
Insulin therapy for type 2 diabetes patients dr shahjadaselim1Insulin therapy for type 2 diabetes patients dr shahjadaselim1
Insulin therapy for type 2 diabetes patients dr shahjadaselim1
Bangabandhu Sheikh Mujib Medical University
 

What's hot (20)

Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 
Insulin therapy dr shahjadaselim
Insulin therapy dr shahjadaselimInsulin therapy dr shahjadaselim
Insulin therapy dr shahjadaselim
 
Basics of insulin therapy
Basics of insulin therapy Basics of insulin therapy
Basics of insulin therapy
 
Insulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetesInsulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetes
 
Management of inpatient hyperglycemia
Management of inpatient hyperglycemiaManagement of inpatient hyperglycemia
Management of inpatient hyperglycemia
 
hypoglycemia
hypoglycemiahypoglycemia
hypoglycemia
 
DKA
DKADKA
DKA
 
Managing Diabetes With Insulin by Dr Shahjada Selim
Managing DiabetesWith Insulin by Dr Shahjada SelimManaging DiabetesWith Insulin by Dr Shahjada Selim
Managing Diabetes With Insulin by Dr Shahjada Selim
 
HYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCYHYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCY
 
Hyperosmolar hyperglycemic state
Hyperosmolar hyperglycemic stateHyperosmolar hyperglycemic state
Hyperosmolar hyperglycemic state
 
Atrial Fibrillation
Atrial FibrillationAtrial Fibrillation
Atrial Fibrillation
 
2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf
 
Insulin in icu 2
Insulin in icu 2Insulin in icu 2
Insulin in icu 2
 
Hypoglycemia in Adults
Hypoglycemia in AdultsHypoglycemia in Adults
Hypoglycemia in Adults
 
Insulin22
Insulin22Insulin22
Insulin22
 
Diabetes care in hospital
Diabetes care in hospitalDiabetes care in hospital
Diabetes care in hospital
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
 
Insulin therapy in IDDM by Dr. Dilip
Insulin therapy in IDDM by Dr. DilipInsulin therapy in IDDM by Dr. Dilip
Insulin therapy in IDDM by Dr. Dilip
 
Hyperglycaemic emergencies in Diabetes mellitus
Hyperglycaemic emergencies in Diabetes mellitusHyperglycaemic emergencies in Diabetes mellitus
Hyperglycaemic emergencies in Diabetes mellitus
 
Insulin therapy for type 2 diabetes patients dr shahjadaselim1
Insulin therapy for type 2 diabetes patients dr shahjadaselim1Insulin therapy for type 2 diabetes patients dr shahjadaselim1
Insulin therapy for type 2 diabetes patients dr shahjadaselim1
 

Viewers also liked

Insulin Therapy in Pregnant Women
Insulin Therapy in Pregnant WomenInsulin Therapy in Pregnant Women
Insulin Therapy in Pregnant Women
bajah423
 
Insulin therapy in the management of diabetes
Insulin therapy in the management of diabetesInsulin therapy in the management of diabetes
Insulin therapy in the management of diabetes
Mashfiqul Hasan
 
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Bangabandhu Sheikh Mujib Medical University
 
Common errors in insulin therapy
Common errors in insulin therapy Common errors in insulin therapy
Common errors in insulin therapy
gauravpalikhe1980
 
Ueda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayedUeda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayed
ueda2015
 
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanemUeda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
ueda2015
 
Aace algorithm
Aace algorithmAace algorithm
Aace algorithm
Tania Mayagoitia
 
Alternative to insulin for gestational diabetes
Alternative to insulin for gestational diabetesAlternative to insulin for gestational diabetes
Alternative to insulin for gestational diabetes
muhammad al hennawy
 
Chapter 8 parenterals
Chapter 8 parenteralsChapter 8 parenterals
Chapter 8 parenterals
Ann Bentley
 
Influenza
InfluenzaInfluenza
Insulin initiation adjustment by Dr Shahjada Selim
Insulin initiation adjustment by Dr Shahjada SelimInsulin initiation adjustment by Dr Shahjada Selim
Insulin initiation adjustment by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Lecture Two: Patient Assessment Definitions
Lecture Two: Patient Assessment DefinitionsLecture Two: Patient Assessment Definitions
Lecture Two: Patient Assessment Definitions
Anas Bahnassi أنس البهنسي
 
KOSPEN: Challenges in empowering the community
KOSPEN: Challenges in empowering the communityKOSPEN: Challenges in empowering the community
KOSPEN: Challenges in empowering the community
PPPKAM
 
Urinary Tract Infections
Urinary Tract InfectionsUrinary Tract Infections
Urinary Tract Infections
Anas Bahnassi أنس البهنسي
 
Lecture two management cycle Part: 2
Lecture two management cycle Part: 2Lecture two management cycle Part: 2
Lecture two management cycle Part: 2
Anas Bahnassi أنس البهنسي
 
Lecture # 01, introduction to pharmacy
Lecture # 01, introduction to pharmacyLecture # 01, introduction to pharmacy
Lecture # 01, introduction to pharmacy
PakistanPharmaCareerDoor
 
Ueda2015 type 2 dm management dr.mesbah kamel
Ueda2015  type 2 dm management dr.mesbah kamelUeda2015  type 2 dm management dr.mesbah kamel
Ueda2015 type 2 dm management dr.mesbah kamel
ueda2015
 
Lecture Three: Initial Patient Assessment
Lecture Three: Initial Patient AssessmentLecture Three: Initial Patient Assessment
Lecture Three: Initial Patient Assessment
Anas Bahnassi أنس البهنسي
 
Hospital Pharmacy: Lecture Three
Hospital Pharmacy: Lecture Three Hospital Pharmacy: Lecture Three
Hospital Pharmacy: Lecture Three
Anas Bahnassi أنس البهنسي
 

Viewers also liked (20)

Calculating insulin dose
Calculating insulin doseCalculating insulin dose
Calculating insulin dose
 
Insulin Therapy in Pregnant Women
Insulin Therapy in Pregnant WomenInsulin Therapy in Pregnant Women
Insulin Therapy in Pregnant Women
 
Insulin therapy in the management of diabetes
Insulin therapy in the management of diabetesInsulin therapy in the management of diabetes
Insulin therapy in the management of diabetes
 
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
 
Common errors in insulin therapy
Common errors in insulin therapy Common errors in insulin therapy
Common errors in insulin therapy
 
Ueda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayedUeda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayed
 
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanemUeda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
 
Aace algorithm
Aace algorithmAace algorithm
Aace algorithm
 
Alternative to insulin for gestational diabetes
Alternative to insulin for gestational diabetesAlternative to insulin for gestational diabetes
Alternative to insulin for gestational diabetes
 
Chapter 8 parenterals
Chapter 8 parenteralsChapter 8 parenterals
Chapter 8 parenterals
 
Influenza
InfluenzaInfluenza
Influenza
 
Insulin initiation adjustment by Dr Shahjada Selim
Insulin initiation adjustment by Dr Shahjada SelimInsulin initiation adjustment by Dr Shahjada Selim
Insulin initiation adjustment by Dr Shahjada Selim
 
Lecture Two: Patient Assessment Definitions
Lecture Two: Patient Assessment DefinitionsLecture Two: Patient Assessment Definitions
Lecture Two: Patient Assessment Definitions
 
KOSPEN: Challenges in empowering the community
KOSPEN: Challenges in empowering the communityKOSPEN: Challenges in empowering the community
KOSPEN: Challenges in empowering the community
 
Urinary Tract Infections
Urinary Tract InfectionsUrinary Tract Infections
Urinary Tract Infections
 
Lecture two management cycle Part: 2
Lecture two management cycle Part: 2Lecture two management cycle Part: 2
Lecture two management cycle Part: 2
 
Lecture # 01, introduction to pharmacy
Lecture # 01, introduction to pharmacyLecture # 01, introduction to pharmacy
Lecture # 01, introduction to pharmacy
 
Ueda2015 type 2 dm management dr.mesbah kamel
Ueda2015  type 2 dm management dr.mesbah kamelUeda2015  type 2 dm management dr.mesbah kamel
Ueda2015 type 2 dm management dr.mesbah kamel
 
Lecture Three: Initial Patient Assessment
Lecture Three: Initial Patient AssessmentLecture Three: Initial Patient Assessment
Lecture Three: Initial Patient Assessment
 
Hospital Pharmacy: Lecture Three
Hospital Pharmacy: Lecture Three Hospital Pharmacy: Lecture Three
Hospital Pharmacy: Lecture Three
 

Similar to Insulin initiation adjustment

Ueda2016 wark shop - insulin therapy - mohamed mashahit
Ueda2016 wark shop - insulin therapy  - mohamed mashahitUeda2016 wark shop - insulin therapy  - mohamed mashahit
Ueda2016 wark shop - insulin therapy - mohamed mashahit
ueda2015
 
Insulin therapy- art of initiation and titration
Insulin therapy- art of initiation and titrationInsulin therapy- art of initiation and titration
Insulin therapy- art of initiation and titration
Saikumar Dunga
 
د شکر په ناروغانو کې د انسولین پیل کول
د شکر په ناروغانو کې د انسولین پیل کولد شکر په ناروغانو کې د انسولین پیل کول
د شکر په ناروغانو کې د انسولین پیل کول
Asmatullah Sapand
 
Diabetes in clinical practice2
Diabetes in clinical practice2Diabetes in clinical practice2
Diabetes in clinical practice2
Hazem Samy
 
GDM Himani (3).pptx
GDM Himani (3).pptxGDM Himani (3).pptx
GDM Himani (3).pptx
himani529926
 
Diabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptxDiabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptx
Dr.Sajid Hasan
 
Insulin Therapy for Type 2 Diabetes:Update
Insulin Therapy for Type 2 Diabetes:Update Insulin Therapy for Type 2 Diabetes:Update
Insulin Therapy for Type 2 Diabetes:Update
NasserAljuhani
 
Gestational diabetes mellitus (2)
Gestational diabetes mellitus (2)Gestational diabetes mellitus (2)
Gestational diabetes mellitus (2)
Keshav Chandra
 
Pharmacotherapy of diabetes mellitus (DM)
Pharmacotherapy of diabetes mellitus (DM)Pharmacotherapy of diabetes mellitus (DM)
Pharmacotherapy of diabetes mellitus (DM)
Nehal M. Ramadan
 
3.Insulin Rx (1)-converted.pptx
3.Insulin Rx  (1)-converted.pptx3.Insulin Rx  (1)-converted.pptx
3.Insulin Rx (1)-converted.pptx
NicoleMx
 
An update on gdm management
An update on gdm managementAn update on gdm management
An update on gdm management
namkha dorji
 
Investigations of d m
Investigations of d mInvestigations of d m
Investigations of d m
Mohammed Abdulelah
 
Insulin therapy in Diabetes Mellitus Pts
Insulin therapy in Diabetes Mellitus PtsInsulin therapy in Diabetes Mellitus Pts
Insulin therapy in Diabetes Mellitus Pts
Benson59
 
treatment of diabetes mellitus.pptx
treatment of diabetes mellitus.pptxtreatment of diabetes mellitus.pptx
treatment of diabetes mellitus.pptx
Roop
 
Low Carbohydrate Diets
Low Carbohydrate DietsLow Carbohydrate Diets
Low Carbohydrate Diets
freenetdesign
 
MedReg+1 Tremble Diabetes
MedReg+1 Tremble DiabetesMedReg+1 Tremble Diabetes
MedReg+1 Tremble Diabetes
MedReg+1
 
Gdm drnur ho
Gdm drnur hoGdm drnur ho
Gdm drnur ho
Nur Na'imah
 
Hyperglycemia management
Hyperglycemia managementHyperglycemia management
Hyperglycemia management
DrReshma Francis
 
diabetes mellitus in children
diabetes mellitus in childrendiabetes mellitus in children
diabetes mellitus in children
Azad Haleem
 
Overview of Diabetes Medical Devices-8-2022.pptx
Overview of Diabetes Medical Devices-8-2022.pptxOverview of Diabetes Medical Devices-8-2022.pptx
Overview of Diabetes Medical Devices-8-2022.pptx
akramabdalla1
 

Similar to Insulin initiation adjustment (20)

Ueda2016 wark shop - insulin therapy - mohamed mashahit
Ueda2016 wark shop - insulin therapy  - mohamed mashahitUeda2016 wark shop - insulin therapy  - mohamed mashahit
Ueda2016 wark shop - insulin therapy - mohamed mashahit
 
Insulin therapy- art of initiation and titration
Insulin therapy- art of initiation and titrationInsulin therapy- art of initiation and titration
Insulin therapy- art of initiation and titration
 
د شکر په ناروغانو کې د انسولین پیل کول
د شکر په ناروغانو کې د انسولین پیل کولد شکر په ناروغانو کې د انسولین پیل کول
د شکر په ناروغانو کې د انسولین پیل کول
 
Diabetes in clinical practice2
Diabetes in clinical practice2Diabetes in clinical practice2
Diabetes in clinical practice2
 
GDM Himani (3).pptx
GDM Himani (3).pptxGDM Himani (3).pptx
GDM Himani (3).pptx
 
Diabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptxDiabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptx
 
Insulin Therapy for Type 2 Diabetes:Update
Insulin Therapy for Type 2 Diabetes:Update Insulin Therapy for Type 2 Diabetes:Update
Insulin Therapy for Type 2 Diabetes:Update
 
Gestational diabetes mellitus (2)
Gestational diabetes mellitus (2)Gestational diabetes mellitus (2)
Gestational diabetes mellitus (2)
 
Pharmacotherapy of diabetes mellitus (DM)
Pharmacotherapy of diabetes mellitus (DM)Pharmacotherapy of diabetes mellitus (DM)
Pharmacotherapy of diabetes mellitus (DM)
 
3.Insulin Rx (1)-converted.pptx
3.Insulin Rx  (1)-converted.pptx3.Insulin Rx  (1)-converted.pptx
3.Insulin Rx (1)-converted.pptx
 
An update on gdm management
An update on gdm managementAn update on gdm management
An update on gdm management
 
Investigations of d m
Investigations of d mInvestigations of d m
Investigations of d m
 
Insulin therapy in Diabetes Mellitus Pts
Insulin therapy in Diabetes Mellitus PtsInsulin therapy in Diabetes Mellitus Pts
Insulin therapy in Diabetes Mellitus Pts
 
treatment of diabetes mellitus.pptx
treatment of diabetes mellitus.pptxtreatment of diabetes mellitus.pptx
treatment of diabetes mellitus.pptx
 
Low Carbohydrate Diets
Low Carbohydrate DietsLow Carbohydrate Diets
Low Carbohydrate Diets
 
MedReg+1 Tremble Diabetes
MedReg+1 Tremble DiabetesMedReg+1 Tremble Diabetes
MedReg+1 Tremble Diabetes
 
Gdm drnur ho
Gdm drnur hoGdm drnur ho
Gdm drnur ho
 
Hyperglycemia management
Hyperglycemia managementHyperglycemia management
Hyperglycemia management
 
diabetes mellitus in children
diabetes mellitus in childrendiabetes mellitus in children
diabetes mellitus in children
 
Overview of Diabetes Medical Devices-8-2022.pptx
Overview of Diabetes Medical Devices-8-2022.pptxOverview of Diabetes Medical Devices-8-2022.pptx
Overview of Diabetes Medical Devices-8-2022.pptx
 

More from Bangabandhu Sheikh Mujib Medical University

Future of DM management by Dr Shahjada Selim
Future of DM management by Dr Shahjada SelimFuture of DM management by Dr Shahjada Selim
Future of DM management by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Gynecomastia by Dr Shahjada Selim
Gynecomastia by Dr Shahjada SelimGynecomastia by Dr Shahjada Selim
Gynecomastia by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Osteoporosis an update-Dr Selim
Osteoporosis an update-Dr SelimOsteoporosis an update-Dr Selim
Osteoporosis an update-Dr Selim
Bangabandhu Sheikh Mujib Medical University
 
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimEmpagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Approach to optimal diabetes care by Dr Shahajda Selim
Approach to optimal diabetes care by Dr Shahajda SelimApproach to optimal diabetes care by Dr Shahajda Selim
Approach to optimal diabetes care by Dr Shahajda Selim
Bangabandhu Sheikh Mujib Medical University
 
Overview of male infertility by Dr Dhahjada Selim
Overview of male infertility by Dr Dhahjada SelimOverview of male infertility by Dr Dhahjada Selim
Overview of male infertility by Dr Dhahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Genetics to environment to T1DM by Dr Shahjada Selim
Genetics to environment to T1DM by Dr Shahjada SelimGenetics to environment to T1DM by Dr Shahjada Selim
Genetics to environment to T1DM by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Type 1 Diabetes: Dr Shahjada Selim
Type 1 Diabetes: Dr Shahjada SelimType 1 Diabetes: Dr Shahjada Selim
Type 1 Diabetes: Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Thyroid disorders- an overview- Dr Shahjada Selim
Thyroid disorders- an overview- Dr Shahjada SelimThyroid disorders- an overview- Dr Shahjada Selim
Thyroid disorders- an overview- Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Thyroid Disorders in Pregnancy- Dr Shahjada Selim
Thyroid Disorders in Pregnancy- Dr Shahjada SelimThyroid Disorders in Pregnancy- Dr Shahjada Selim
Thyroid Disorders in Pregnancy- Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Erectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Erectile Dysfunction:Evaluation and Management by Dr Shahjada SelimErectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Erectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Hypothyroidism: Evaluation & Management by Dr Selim
Hypothyroidism: Evaluation & Management by Dr SelimHypothyroidism: Evaluation & Management by Dr Selim
Hypothyroidism: Evaluation & Management by Dr Selim
Bangabandhu Sheikh Mujib Medical University
 
Sexual Response Cycle- Dr Shahjada Selim
Sexual Response Cycle- Dr Shahjada SelimSexual Response Cycle- Dr Shahjada Selim
Sexual Response Cycle- Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Diabetes and Sexual Dysfunction -Dr Shahjada Seliml
Diabetes and Sexual Dysfunction -Dr Shahjada SelimlDiabetes and Sexual Dysfunction -Dr Shahjada Seliml
Diabetes and Sexual Dysfunction -Dr Shahjada Seliml
Bangabandhu Sheikh Mujib Medical University
 
Menopause Dr Shahjada Selim
Menopause Dr Shahjada SelimMenopause Dr Shahjada Selim
Menopause Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Menopause by Dr Shahjada Selim
Menopause by Dr Shahjada SelimMenopause by Dr Shahjada Selim
Menopause by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada SelimMenopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Diagnostic Tests of Diabetes
Diagnostic Tests of DiabetesDiagnostic Tests of Diabetes
Diagnostic Tests of Diabetes
Bangabandhu Sheikh Mujib Medical University
 
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada SelimMale Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada SelimVitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 

More from Bangabandhu Sheikh Mujib Medical University (20)

Future of DM management by Dr Shahjada Selim
Future of DM management by Dr Shahjada SelimFuture of DM management by Dr Shahjada Selim
Future of DM management by Dr Shahjada Selim
 
Gynecomastia by Dr Shahjada Selim
Gynecomastia by Dr Shahjada SelimGynecomastia by Dr Shahjada Selim
Gynecomastia by Dr Shahjada Selim
 
Osteoporosis an update-Dr Selim
Osteoporosis an update-Dr SelimOsteoporosis an update-Dr Selim
Osteoporosis an update-Dr Selim
 
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimEmpagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
 
Approach to optimal diabetes care by Dr Shahajda Selim
Approach to optimal diabetes care by Dr Shahajda SelimApproach to optimal diabetes care by Dr Shahajda Selim
Approach to optimal diabetes care by Dr Shahajda Selim
 
Overview of male infertility by Dr Dhahjada Selim
Overview of male infertility by Dr Dhahjada SelimOverview of male infertility by Dr Dhahjada Selim
Overview of male infertility by Dr Dhahjada Selim
 
Genetics to environment to T1DM by Dr Shahjada Selim
Genetics to environment to T1DM by Dr Shahjada SelimGenetics to environment to T1DM by Dr Shahjada Selim
Genetics to environment to T1DM by Dr Shahjada Selim
 
Type 1 Diabetes: Dr Shahjada Selim
Type 1 Diabetes: Dr Shahjada SelimType 1 Diabetes: Dr Shahjada Selim
Type 1 Diabetes: Dr Shahjada Selim
 
Thyroid disorders- an overview- Dr Shahjada Selim
Thyroid disorders- an overview- Dr Shahjada SelimThyroid disorders- an overview- Dr Shahjada Selim
Thyroid disorders- an overview- Dr Shahjada Selim
 
Thyroid Disorders in Pregnancy- Dr Shahjada Selim
Thyroid Disorders in Pregnancy- Dr Shahjada SelimThyroid Disorders in Pregnancy- Dr Shahjada Selim
Thyroid Disorders in Pregnancy- Dr Shahjada Selim
 
Erectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Erectile Dysfunction:Evaluation and Management by Dr Shahjada SelimErectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Erectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
 
Hypothyroidism: Evaluation & Management by Dr Selim
Hypothyroidism: Evaluation & Management by Dr SelimHypothyroidism: Evaluation & Management by Dr Selim
Hypothyroidism: Evaluation & Management by Dr Selim
 
Sexual Response Cycle- Dr Shahjada Selim
Sexual Response Cycle- Dr Shahjada SelimSexual Response Cycle- Dr Shahjada Selim
Sexual Response Cycle- Dr Shahjada Selim
 
Diabetes and Sexual Dysfunction -Dr Shahjada Seliml
Diabetes and Sexual Dysfunction -Dr Shahjada SelimlDiabetes and Sexual Dysfunction -Dr Shahjada Seliml
Diabetes and Sexual Dysfunction -Dr Shahjada Seliml
 
Menopause Dr Shahjada Selim
Menopause Dr Shahjada SelimMenopause Dr Shahjada Selim
Menopause Dr Shahjada Selim
 
Menopause by Dr Shahjada Selim
Menopause by Dr Shahjada SelimMenopause by Dr Shahjada Selim
Menopause by Dr Shahjada Selim
 
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada SelimMenopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
 
Diagnostic Tests of Diabetes
Diagnostic Tests of DiabetesDiagnostic Tests of Diabetes
Diagnostic Tests of Diabetes
 
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada SelimMale Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
 
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada SelimVitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
 

Recently uploaded

Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 

Recently uploaded (20)

Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 

Insulin initiation adjustment

  • 1. Insulin Therapy Initiation and Adjustment Dr Shahjada Selim Endocrinologist Registrar, Department of Medicine, ShSMCH 1
  • 2. Issues in the Management of Type 2 Diabetes • Type 2 DM is a chronic condition with progressive loss of beta-cell function over time • Increasing prevalence with obesity • Hyperglycemia affects morbidity, mortality • Tight glycemic control with insulin may reduce costly complications 2
  • 3. 3 • 30% to 40% of patients ultimately require insulin. • Newer semisynthetic or analog insulins and delivery systems may improve compliance and achieve better glycemic control with less hypoglycemia. …………………Conted
  • 4. Defined glycemic targets in T2DM PG=plasma glucose. 1. American Diabetes Association. Diabetes Care 2005;28(suppl 1):S14—36. 2. American Association of Clinical Endocrinologists. Endocr Pract 2002;8(suppl 1):43—84. 3. International Diabetes Federation. Diabet Med 1999;16:716—30. *1−2 hours postprandial; **2 hours postprandial. Glucose control Healthy ADA1 AACE2 IDF3 HbA1c (%) <6 <7 ≤6.5 ≤6.5 Mean FPG mmol/l (mg/dl) <5.6 (<100) 5−7.2 (90−130) <6 (<110) <6 (<110) Mean postprandial PG mmol/l (mg/dl) <7.8 (<140) <10* (<180) <7.8** (<140) <7.5** (<135) 4
  • 5. The Goal of Insulin Therapy: Attempt to Mimic Normal Pancreatic Function Schade, Skyler, Santiago, Rizza, “Intensive Insulin Therapy,” 1993, p. 131. 0 6 0 3 0 1 0 0 6 0 1 4 0 1 5 1 9 3 0 H O U R S 2 3 3 0 0 3 3 0 0 7 3 01 5 3 01 1 3 03 3 0 8 0 4 0 1 2 0 7 5 1 6 0 P L A S M A G L U C O S E m g / d l B L S H S P L A S M A F R E E IN S U L IN u / m l
  • 6. Purpose of Insulin Therapy • Prevent and treat fasting and postprandial hyperglycemia • Permit appropriate utilization of glucose and other nutrients by peripheral tissues • Suppress hepatic glucose production • Prevent acute complications of uncontrolled diabetes • Prevent long term complications of chronic diabetes 6
  • 7. All type 1 diabetics should be on a Bolus-bolus insulin regimen to control glucose while minimizing hypoglycemia. 6-19
  • 8. However over time, most type 2 diabetics will also need both basal and mealtime insulin to control glucose. 6-19
  • 10. Patient Concerns About Insulin • Fear of injections • Perceived significance of need for insulin • Worries that insulin could worsen diabetes • Concerns about hypoglycemia • Complexity of regimens 10
  • 11. When to Start Insulin? • Watch for the following signs – Increasing BG levels – Elevated A1C – Unexplained weight loss – Traces of ketonuria – Poor energy level 11 When OHAs are not enough to achieve target glycemic status --
  • 12. …..When Oral Medications Are Not Enough – Sleep disturbances – Polydipsia • Next steps – Make a decision to start insulin – Offer patient encouragement, not blame 12
  • 13. …..Initiating Insulin Therapy in Type 2 Diabetes • Let blood glucose levels guide choice of insulins – Select type(s) of insulin and timing of injection(s) based on pattern of patient’s sugar (fasting, lunch, dinner, bedtime) 13
  • 14. ….Initiating Insulin Therapy in Type 2 Diabetes • Choose from currently available insulin preparations – Rapid-acting (mealtime): lispro, aspart, glulisine – Short-acting (mealtime): regular insulin – Intermediate-acting (background): NPH, lente – Long-acting (background): degledec, ultralente, glargine – Insulin mixtures (premixed)
  • 15. ….Initiating Insulin Therapy in Type 2 Diabetes • Provide long-acting or intermediate- acting as basal and rapid-acting as bolus • Titrate every week Goal: to approximate endogenous insulin secretion…
  • 16. The ADA TreatmentThe ADA Treatment Algorithm for the Initiation andAlgorithm for the Initiation and Adjustment of InsulinAdjustment of Insulin 16
  • 17. Step One: Initiating InsulinStep One: Initiating Insulin • Start with either… – Bedtime long-acting/intermediate acting insulin Insulin regimens should be designed taking lifestyle and meal schedules into account Nathan DM et al. Diabetes Care 2006;29(8):1963-72.17
  • 18. Step One: Initiating InsulinStep One: Initiating Insulin, cont’d, cont’d • Check fasting glucose and increase dose until in target range – Target range: 3.89-7.22 mmol/l (70-130 mg/dl) – Typical dose increase is 2 units every 3 days, but if fasting glucose >10 mmol/l (>180 mg/dl), can increase by large increments (e.g., 4 units every 3 days). Nathan DM et al. Diabetes Care 2006;29(8):1963-72.18
  • 19. • If hypoglycemia occurs or if fasting glucose >3.89 mmol/l (70 mg/dl)… – Reduce bedtime dose by ≥4 units or 10% if dose >60 units Step One: Initiating InsulinStep One: Initiating Insulin, cont’d, cont’d Nathan DM et al. Diabetes Care 2006;29(8):1963-72.19
  • 20. • If HbA1c is <7%... – Continue regimen and check HbA1c every 3 months • If HbA1c is ≥7%... – Move to Step Two… After 2-3 Months…After 2-3 Months… Nathan DM et al. Diabetes Care 2006;29(8):1963-72.20
  • 21. Initiating and Adjusting InsulinInitiating and Adjusting Insulin Continue regimen; check HbA1c every 3 months If fasting BG in target range, check BG before lunch, dinner, and bed. Depending on BG results, add second injection (can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range) Recheck pre-meal BG levels and if out of range, may need to add another injection; if HbA1c continues to be out of range, check 2-hr postprandial levels and adjust preprandial rapid-acting insulin If HbA1c ≤7%... Bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin (initiate with 10 units or 0.2 units per kg) Check FG and increase dose until in target range. If HbA1c ≥7%... Hypoglycemia or FG >3.89 mmol/l (70 mg/dl): Reduce bedtime dose by ≥4 units (or 10% if dose >60 units) Pre-lunch BG out of range: add rapid-acting insulin at breakfast Pre-dinner BG out of range: add NPH insulin at breakfast or rapid-acting insulin at lunch Pre-bed BG out of range: add rapid-acting insulin at dinner Continue regimen; check HbA1c every 3 months Target range: 3.89-7.22 mmol/L (70-130 mg/dL) Nathan DM et al. Diabetes Care. 2006;29(8):1963-72. If HbA1c ≤7%... If HbA1c ≥7%... 21
  • 22. Step One… Continue regimen; check HbA1c every 3 months If fasting BG in target range, check BG before lunch, dinner, and bed. Depending on BG results, add second injection (can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range) Recheck pre-meal BG levels and if out of range, may need to add another injection; if HbA1c continues to be out of range, check 2-hr postprandial levels and adjust preprandial rapid-acting insulin If HbA1c ≤7%... Bedtime long-acting insulin (initiate with 10 units or 0.2 units per kg) Check FG and increase dose until in target range. If HbA1c ≥7%... Hypoglycemia or FG >3.89 mmol/l (70 mg/dl): Reduce bedtime dose by ≥4 units (or 10% if dose >60 units) Pre-lunch BG out of range: add rapid-acting insulin at breakfast Pre-dinner BG out of range: add NPH insulin at breakfast or rapid-acting insulin at lunch Pre-bed BG out of range: add rapid-acting insulin at dinner Continue regimen; check HbA1c every 3 months Target range: 3.89-7.22 mmol/L (70-130 mg/dL) If HbA1c ≤7%... If HbA1c ≥7%... Nathan DM et al. Diabetes Care. 2006;29(8):1963-72. 22
  • 23. Step Two: Intensifying InsulinStep Two: Intensifying Insulin If fasting blood glucose levels are in target range but HbA1c ≥7%, check blood glucose before lunch, dinner, and bed and add a second injection: Nathan DM et al. Diabetes Care 2006;29(8):1963-72.23
  • 24. Step Two: Intensifying InsulinStep Two: Intensifying Insulin • If pre-lunch blood glucose is out of range, add rapid-acting insulin at breakfast • If pre-dinner blood glucose is out of range, add NPH insulin at breakfast or rapid- acting insulin at lunch • If pre-bed blood glucose is out of range, add rapid-acting insulin at dinner Nathan DM et al. Diabetes Care 2006;29(8):1963-72.24
  • 25. Insulin AdjustmentsInsulin Adjustments • Can usually begin with ~4 units and adjust by 2 units every 3 days until blood glucose is in range. Nathan DM et al. Diabetes Care 2006;29(8):1963-72.25
  • 26. • If HbA1c is <7%... – Continue regimen and check HbA1c every 3 months • If HbA1c is ≥7%... – Move to Step Three… After 2-3 Months…After 2-3 Months… Nathan DM et al. Diabetes Care 2006;29(8):1963-72.26
  • 27. Continue regimen; check HbA1c every 3 months If fasting BG in target range, check BG before lunch, dinner, and bed. Depending on BG results, add second injection (can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range) Recheck pre-meal BG levels and if out of range, may need to add another injection; if HbA1c continues to be out of range, check 2-hr postprandial levels and adjust preprandial rapid-acting insulin If HbA1c ≤7%... Bedtime long-acting insulin (initiate with 10 units or 0.2 units per kg) Check FG and increase dose until in target range. If HbA1c ≥7%... Hypoglycemia or FG >3.89 mmol/l (70 mg/dl): Reduce bedtime dose by ≥4 units (or 10% if dose >60 units) Pre-lunch BG out of range: add rapid-acting insulin at breakfast Pre-dinner BG out of range: add NPH insulin at breakfast or rapid-acting insulin at lunch Pre-bed BG out of range: add rapid-acting insulin at dinner Continue regimen; check HbA1c every 3 months Target range: 3.89-7.22 mmol/L (70-130 mg/dL) If HbA1c ≤7%... If HbA1c ≥7%... Step Two… Nathan DM et al. Diabetes Care. 2006;29(8):1963-72. 27
  • 28. Step Three:Step Three: Further Intensifying InsulinFurther Intensifying Insulin • Recheck pre-meal blood glucose and if out of range, may need to add a third injection: • If HbA1c is still ≥ 7% –Check 2-hr postprandial levels –Adjust preprandial rapid-acting insulin Nathan DM et al. Diabetes Care 2006;29(8):1963-72.28
  • 29. Nathan DM et al. Diabetes Care. 2006;29(8):1963-72. Continue regimen; check HbA1c every 3 months If fasting BG in target range, check BG before lunch, dinner, and bed. Depending on BG results, add second injection (can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range) Recheck pre-meal BG levels and if out of range, may need to add another injection; if HbA1c continues to be out of range, check 2-hr postprandial levels and adjust preprandial rapid-acting insulin If HbA1c ≤7%... Bedtime long-acting insulin (initiate with 10 units or 0.2 units per kg) Check FG and increase dose until in target range. If HbA1c ≥7%... Hypoglycemia or FG >3.89 mmol/l (70 mg/dl): Reduce bedtime dose by ≥4 units (or 10% if dose >60 units) Pre-lunch BG out of range: add rapid-acting insulin at breakfast Pre-dinner BG out of range: add NPH insulin at breakfast or rapid-acting insulin at lunch Pre-bed BG out of range: add rapid-acting insulin at dinner Continue regimen; check HbA1c every 3 months Target range: 3.89-7.22 mmol/L (70-130 mg/dL) If HbA1c ≤7%... If HbA1c ≥7%... Step Three… 29
  • 30. Premixed InsulinPremixed Insulin • Not recommended during dose adjustment . • Can be used before breakfast and/or dinner if the proportion of rapid- and intermediate-acting insulin is similar to the fixed proportions available Nathan DM et al. Diabetes Care 2006;29(8):1963-72.30
  • 31. Basal Insulins in Type 2 DM • NPH at HS - duration of action short: - usually need AM injection - nighttime hypoglycemia a problem 31
  • 32. Basal Insulins in Type 2 DM • Analogs - Degludec - true once daily injection - Glargin - likely to succeed as true once daily injection - Detemir – Basal insulin 32
  • 33. Inhaled InsulinInhaled Insulin • Approved in the U.S. in 2006 for the treatment of type 2 diabetes and then had been withdrawn from the market. • In June, 2014 another inhaled insulin (Afreeza) got US FDA approval and Aventis bought the patent of it for commercial production and marketing. Nathan DM et al. Diabetes Care 2006;29(8):1963-72.33
  • 34. Upgrade and Intensification Selecting alternative insulin or altering the current treatment regimen (e.g. Increasing number of daily doses)
  • 35. Need of Changing Insulin Regimen • Failure to attain or maintain target glycemic status (FPG/PPG or HbA1C). • H/O repeated hypoglycemia • Lifestyle issues
  • 36. Changing from Other regimens to Basal/Bolus Insulin ~50% Basal* Total Daily DoseTotal Daily Dose (~70-75% of prior insulin regimen TDD)(~70-75% of prior insulin regimen TDD) ~50% Bolus* Usually divided into 3 premealUsually divided into 3 premeal dosesdoses*Range: 40 to 60%*Range: 40 to 60%
  • 37. An Example: • Mr. M: 58 yrs with history type 2 diabetes for 8 years – In addition to OHAs, he is on 70/30 premixed insulin: 30 u AM and 15 u PM – Current Total Daily Dose = 45 u of 70/30 – However, he has been having difficulty with wide glycemic excursions.
  • 38. ………….An Example: • After discussing his options in detail, he is willing to begin with basal/bolus regimen: • New TDD= 45 u x .75 = 33.75 = 34 u – Basal = 17 u Degludec at bedtime – Bolus = 17 u total / 3 = 5.6 u = 5 u aspart/Glulisine immediately before meals.
  • 39. Another method • Same patient: Mr. M on 70/30 insulin: 30 u AM and 15 u PM – Current Total Daily Dose = 45 u of 70/30 • Instead, some clinicians prefer to instead calculate the new basal/bolus doses independently of each other – Current Basal= 0.70 x 45 u TDD = 31.5 u N – Current Bolus= 0.30 x 45 u TDD = 13.5 u.
  • 40. ………….Another method • Then, use 70 to 75% of prior NPH, but divide prior short acting into 3 premeal doses – New Basal= 0.75 x 31.5 u N = 24 u Degludec, Glargine, Detemir. – New Bolus= 13.5 u R / 3 = 4.5 u (round up or down) Aspart or Glulisine
  • 41. So which method is best? • This is where the “Art of Medicine” comes in: – If patient has been having difficulty with hypoglycemia, then start any new insulin regimen with conservative doses. – If patient, on the other hand, has been having hyperglycemia, then one can be more aggressive. Remember: every patient is an individual!
  • 42. A Quick Word on using Sliding Scale Insulin…. Don’t!
  • 43. Instead of Sliding Scale.... • Basal insulin is necessary even in the fasting state • Sliding scales do not provide physiologic insulin needs • Sliding scales often result in “chasing” of blood sugars • There can be wide glycemic excursions Remember: Just because a diabetic’s FBG is <150 does not mean that they need no insulin! Think Supplementation or Correction Scale…
  • 44.
  • 45. The Solution: • In acutely ill hospitalized diabetics: use continuous IV insulin
  • 46. ………The Solution: • If one must use an insulin scale in an outpatient or stable inpatient setting: • Insulin scale should only supplement a routine scheduled regimen of basal and premeal insulin • May use to correct for hyperglycemia between scheduled doses of insulin • It should NEVER be ordered such that the scale is the only source of insulin for the patient
  • 47. Drawbacks of intensive insulin regimens • Requires frequent monitoring of glucose • Multiple daily injections of insulin • Requires intensive patient education/on- going support • Newer insulin analogues require less injections a but are more expensive 47
  • 48. Key Take-Home MessagesKey Take-Home Messages • Insulin is the oldest, most studied, and most effective antihyperglycemic agent, but can cause weight gain (2-4 kg) and hypoglycemia. • Insulin analogues with longer, non-peaking profiles may decrease the risk of hypoglycemia compared with NPH insulin. 48
  • 49. Key Take-Home MessagesKey Take-Home Messages • Premixed insulin is not recommended during dose adjustment. 49
  • 50. Key Take-Home MessagesKey Take-Home Messages • When initiating insulin, start with bedtime or morning long-acting insulin. • After 2-3 months, if FBG levels are in target range but HbA1c ≥7%, check BG before lunch, dinner, and bed, and, depending on the results, add 2nd injection. 50
  • 51. Key Take-Home MessagesKey Take-Home Messages • After 2-3 months, if pre-meal BG out of range, may need to add a 3rd injection; if HbA1c is still ≥7% check 2-hr postprandial levels and adjust preprandial rapid-acting insulin. • Adjust one insulin at a time. Begin with the insulin that will correct the first problem blood glucose of the day. 51
  • 52. Key Take-Home MessagesKey Take-Home Messages • It is difficult to obtain optimal control without occasional, mild episodes of hypoglycemia. 52

Editor's Notes

  1. Slide 6-19 MIMICKING NATURE WITH INSULIN THERAPY Over time, most patients will need both basal and mealtime insulin to control glucose Since both fasting and postprandial glucose levels are abnormal in type 2 diabetes and the underlying insulin deficiency typically progresses, most patients will need both basal insulin and mealtime insulin if excellent glucose control is to be maintained. The goal of intensive insulin therapy is to delay the onset of microvascular complications and retard their progression once they occur.
  2. Slide 6-19 MIMICKING NATURE WITH INSULIN THERAPY Over time, most patients will need both basal and mealtime insulin to control glucose Since both fasting and postprandial glucose levels are abnormal in type 2 diabetes and the underlying insulin deficiency typically progresses, most patients will need both basal insulin and mealtime insulin if excellent glucose control is to be maintained. The goal of intensive insulin therapy is to delay the onset of microvascular complications and retard their progression once they occur.
  3. Slide 6-36 Overcoming Complexity by Starting With Basal Insulin One way to overcome the complexity of multiple daily insulin injection regimens is to start with basal insulin in patients with type 2 diabetes who are no longer responding adequately to oral agents.
  4. As described, patients often proceed from taking a single oral medication to taking 2 or more oral agents or a combination of oral medication with insulin. Commonly, insulin is initiated in a schedule with intermediate- or long-acting insulin at bedtime to control fasting glucose levels and oral medications to control daytime glucose levels.
  5. As described, patients often proceed from taking a single oral medication to taking 2 or more oral agents or a combination of oral medication with insulin. Commonly, insulin is initiated in a schedule with intermediate- or long-acting insulin at bedtime to control fasting glucose levels and oral medications to control daytime glucose levels.
  6. Key Point When initiating insulin, the ADA recommends beginning with either a bedtime intermediate-acting insulin or a bedtime or morning long-acting insulin. This can be initiated with 10 units or 0.2 units per kilogram. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  7. Key Points Fasting glucose should be checked daily via fingerstick and the dose should be increased, typically by 2 units every 3 days, until fasting levels are in the target range (i.e., 3.89-7.22 mmol/l or 70-130 mg/dl). If fasting glucose is over 10 mmol/l (i.e., over 180 mg/dl), doses can be increased in larger increments (for example, by 4 units every 3 days). All insulin regimens should be designed to take lifestyle and meal schedules into account. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  8. Key Points HbA1c should be re-checked within 2 to 3 months. If it is below 7%, the current regimen should be continued with re-evaluation of HbA1c levels every 3 months. If it is 7% or higher, physicians should move to Step Two of the algorithm. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  9. Key Points Although initial therapy is aimed at increasing basal insulin supply, usually with intermediate- or long-acting insulin, patients may also require prandial therapy with short- or rapid-acting insulin as well. The ADA algorithm has been created to help guide physicians in determining a patient’s optimal insulin regimen. There are three steps to the algorithm. Each will be reviewed in turn. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  10. Key Point Step one involves initiating insulin. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  11. Key Points If, after 2 to 3 months of initiating insulin therapy, fasting blood glucose levels are in target range but HbA1c is 7% or higher, the patient’s blood glucose should be checked before lunch, dinner, and bed, and a second injection should be added. If the patient’s pre-lunch blood glucose is out of range, rapid-acting insulin should be added at breakfast. If pre-dinner blood glucose is out of range, NPH insulin should be added at breakfast or rapid-acting insulin should be added at lunch. If pre-bed blood glucose is out of range, rapid-acting insulin should be added at dinner. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  12. Key Points If, after 2 to 3 months of initiating insulin therapy, fasting blood glucose levels are in target range but HbA1c is 7% or higher, the patient’s blood glucose should be checked before lunch, dinner, and bed, and a second injection should be added. If the patient’s pre-lunch blood glucose is out of range, rapid-acting insulin should be added at breakfast. If pre-dinner blood glucose is out of range, NPH insulin should be added at breakfast or rapid-acting insulin should be added at lunch. If pre-bed blood glucose is out of range, rapid-acting insulin should be added at dinner. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  13. Key Points Again, HbA1c should be re-checked within 2 to 3 months. If it is below 7%, the current regimen should be continued with re-evaluation of HbA1c levels every 3 months. If it is 7% or higher, physicians should move to Step Three of the algorithm. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  14. Key Point Step Two of the algorithm involves intensifying insulin therapy. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  15. Key Points If pre-meal blood glucose is out of range when rechecked, a third injection of insulin may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  16. Key Point Step Three of the algorithm involves further intensifying insulin therapy. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  17. Key Points Premixed insulin is not recommended during dose adjustment. However, it can be used conveniently, usually before breakfast and/or dinner, if the proportion of rapid- and intermediate-acting insulin is similar to the fixed proportions available. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  18. Key Points Inhaled insulin was approved in the U.S. in 2006 for the treatment of type 2 diabetes. However, published clinical studies to date have not demonstrated whether inhaled insulin can lower HbA1c to 7% or lower, either as monotherapy or in combination with an injection of long-acting insulin. Reference: Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
  19. Key Points In conclusion: Insulin is the oldest, most studied and most effective antihyperglycemic agent but can cause weight gain (2-4 kg) and, in rare instances, hypoglycemia Insulin analogues with longer, non-peaking profiles may decrease the risk of hypoglycemia compared with NPH insulin Published studies have not demonstrated whether inhaled insulin can lower HbA1c to 7% or lower Premixed insulin is not recommended during dose adjustment
  20. Key Points In conclusion: Insulin is the oldest, most studied and most effective antihyperglycemic agent but can cause weight gain (2-4 kg) and, in rare instances, hypoglycemia Insulin analogues with longer, non-peaking profiles may decrease the risk of hypoglycemia compared with NPH insulin Published studies have not demonstrated whether inhaled insulin can lower HbA1c to 7% or lower Premixed insulin is not recommended during dose adjustment
  21. Key Points (continued from previous): When initiating insulin, patients should start with bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin After 2 to 3 months, if fasting blood glucose levels are in target range but HbA1c is 7% or higher, blood glucose levels should be checked before lunch, dinner and bed, and, depending on the results, a 2nd insulin injection should be added. After 2 to 3 months, if pre-meal blood glucose is out of range, a 3rd injection may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted accordingly.
  22. Key Points (continued from previous): When initiating insulin, patients should start with bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin After 2 to 3 months, if fasting blood glucose levels are in target range but HbA1c is 7% or higher, blood glucose levels should be checked before lunch, dinner and bed, and, depending on the results, a 2nd insulin injection should be added. After 2 to 3 months, if pre-meal blood glucose is out of range, a 3rd injection may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted accordingly.
  23. Key Points (continued from previous): When initiating insulin, patients should start with bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin After 2 to 3 months, if fasting blood glucose levels are in target range but HbA1c is 7% or higher, blood glucose levels should be checked before lunch, dinner and bed, and, depending on the results, a 2nd insulin injection should be added. After 2 to 3 months, if pre-meal blood glucose is out of range, a 3rd injection may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted accordingly.